Pregled bibliografske jedinice broj: 76174
Latanoprost monotherapy is effective antiglaucoma treatment for patients resistant to beta-blockers
Latanoprost monotherapy is effective antiglaucoma treatment for patients resistant to beta-blockers // Book of Abstracts MATH/CHEM/COMP 2002 / Graovac, Ante ; Pokrić, Biserka ; Smrečki, Vilko (ur.).
Zagreb: Institut Ruđer Bošković, 2002. str. 78-78 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 76174 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Latanoprost monotherapy is effective antiglaucoma treatment for patients resistant to beta-blockers
Autori
Štambuk, Nikola ; Pavan, Josip ; Konjevoda, Paško ; Pavan, Doroteja
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Book of Abstracts MATH/CHEM/COMP 2002
/ Graovac, Ante ; Pokrić, Biserka ; Smrečki, Vilko - Zagreb : Institut Ruđer Bošković, 2002, 78-78
Skup
MATH/CHEM/COMP 2002 - The 17th Dubrovnik International Course & Conference on the Interfaces among Mathematics, Chemistry and Computer Sciences
Mjesto i datum
Dubrovnik, Hrvatska, 24.06.2002. - 29.06.2002
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
glaucona; latanoprost; beta-blockers; patients; monotherapy
Sažetak
Glaucoma is a major global cause of blindness. Its prevalence varies between countries and increases with age. Latanoprost (PhXA41) is a prostaglandin analogue which has a novel mechanism of action on intraocular pressure. We analysed ocular hypotensive efficacy of latanoprost (Xalatan), in a clinical trial conducted on 157 patients. Xalatan is a topical solution containing latanoprost 0.005% as the active ingredient. The results of the study indicate that latanoprost (Xalatan) may be an useful therapeutic agent in glaucoma patients resistant to beta-blockers. Chemistry, biochemistry and modes of action of latanoprost will be discussed.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
